Vanguard Group Inc. has increased its stake in Abbott Laboratories (NYSE: ABT) by 0.2% during the third quarter of 2023. The investment firm now holds approximately 173,154,308 shares of the healthcare product manufacturer, having acquired an additional 353,457 shares in the period. As of its most recent filing with the Securities and Exchange Commission (SEC), Vanguard’s holdings are valued at around $23.19 billion, representing about 0.10% of Abbott’s total shares.
Several other institutional investors have also adjusted their positions in Abbott Laboratories recently. Notably, IMG Wealth Management Inc. expanded its stake by a remarkable 759.1% in the second quarter, bringing its total holdings to just 189 shares valued at $26,000. Other firms such as Cloud Capital Management LLC and Guerra Advisors Inc. also took new positions in Abbott during the third quarter, valued at approximately $29,000 and $31,000, respectively.
The landscape of institutional ownership is significant, with hedge funds and institutional investors collectively owning 75.18% of Abbott’s stock. In a related development, Abbott’s Director, Daniel J. Starks, purchased 10,000 shares of the company on February 4, 2024, at an average price of $108.73 per share. This acquisition amounted to a total of $1,087,300, increasing his ownership to approximately 6,738,817 shares, valued at around $732.71 million.
Abbott Laboratories Financial Performance
Abbott Laboratories has experienced fluctuations in its share price recently. On January 22, 2024, the company reported an earnings per share (EPS) of $1.50 for the last quarter, aligning with analysts’ expectations. The company’s total revenue for the quarter was $11.46 billion, slightly below the anticipated $11.80 billion. Despite the revenue miss, Abbott’s quarterly revenue marked a 4.4% increase compared to the same quarter the previous year, where it recorded an EPS of $1.34.
Looking ahead, Abbott Laboratories has set its guidance for the first quarter of 2026 at an EPS range of $1.120 to $1.180, and for the full fiscal year, it anticipates an EPS range of $5.550 to $5.800. Analysts project an average EPS of $5.14 for the current year.
Dividend Announcement and Shareholder Value
In a positive move for shareholders, Abbott Laboratories recently announced an increase in its quarterly dividend, which was paid on February 13, 2024. Shareholders of record as of January 15, 2024, received a dividend of $0.63, up from the previous $0.59. This raises the annualized dividend to $2.52, yielding approximately 2.2%. The ex-dividend date for this payment was also on January 15, 2024, with a dividend payout ratio of 67.74%.
Founded in 1888 and headquartered in Abbott Park, Illinois, Abbott Laboratories develops and markets a wide array of medical products and services. The company operates across various sectors, including diagnostics, medical devices, and nutritionals, providing essential products to hospitals, clinics, and consumers globally. Abbott’s diagnostic capabilities, particularly its Alinity family of instruments, play a crucial role in detecting infectious diseases and chronic conditions.
As institutional investors like Vanguard Group continue to strengthen their positions in Abbott Laboratories, the company’s financial strategies and product offerings remain in focus for market analysts and shareholders alike. For those interested in keeping up with the latest updates on Abbott Laboratories and its stock performance, resources such as HoldingsChannel.com provide ongoing insights into institutional holdings and insider trades.
